Researchers publishing in Neurology on August 26, 2026, revealed a new MRI-based brain scan biomarker that measures gray matter shrinkage to predict the timeline of early-onset Alzheimer’s disease progression from mild cognitive impairment to dementia, offering patients and families clearer expectations for future care.
Tracking the Timeline of Early-Onset Alzheimer’s Disease
For adults diagnosed with early-onset Alzheimer’s disease, the timeline from initial memory issues to full dementia has long remained difficult to forecast. The condition develops before age 65, striking individuals while they are still working or raising families. It typically begins with mild cognitive impairment—thinking and memory problems that exceed normal aging but fall short of a dementia diagnosis. While the condition often advances quickly, the exact trajectory varies widely from patient to patient.
That clinical uncertainty prompted a team of investigators to develop a predictive tool. This is a study driven by one of the most frequent questions we get from patients in the clinic: ‘When will I lose my independence?
said study author Alexandra Touroutoglou, PhD, of Harvard Medical School in Boston, Massachusetts.
“There are limited ways to predict the transition from MCI to dementia, so we developed a brain scan biomarker called the early-onset Alzheimer’s disease signature, a map that can be applied to brain scans to measure shrinkage in regions of the brain involved in thinking such as memory, language and reasoning. Our study found that brain shrinkage measured by our biomarker can act as a timer for predicting when dementia will start and how quickly someone progressed from MCI to dementia.”
Alexandra Touroutoglou, PhD, study author, Harvard Medical School
How the Brain Scan Biomarker Measures Gray Matter Atrophy
The study, published in the official journal of the American Academy of Neurology, evaluated data from 130 individuals living independently with mild cognitive impairment alongside 97 healthy participants. Every participant was between 40 and 64 years old. Researchers examined magnetic resonance imaging scans taken at the start of the research project and during at least one annual follow-up visit.
The newly tested early-onset Alzheimer’s disease signature isolates eight key brain regions involved in thinking and memory. These areas include the medial and lateral parietal cortex as well as the posterior lateral temporal cortex. By calculating the average thickness of these regions and combining them into an overall score, investigators measured gray matter shrinkage across the cohorts.
Participants were tracked for an average of two years. During that monitoring window, approximately 65 percent of the participants with early-onset Alzheimer’s disease progressed from mild cognitive impairment to dementia.
Predicting Faster Progression Through Standard Deviation Scores
The findings indicate that greater gray matter atrophy visible on brain scans correlates directly with a faster transition to dementia. Statistical evaluations showed that an individual’s risk of progressing from mild cognitive impairment to dementia increased by 1.24 times for every one standard deviation increase in the magnitude of brain shrinkage.
Crucially, the biomarker proved more effective at predicting individual disease trajectories than relying solely on clinical symptoms observed at the baseline evaluation.
Institutional Support
“This brain scan biomarker we developed may help predict how quickly the disease will progress in each individual, giving physicians, people with early-onset Alzheimer’s disease and their families better information about what to expect and allowing earlier clinical trial enrollment for treatments that may improve outcomes.”
Alexandra Touroutoglou, PhD, Harvard Medical School
По теме
